Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.57 |
| ▸ | CES1 | P23141 | 4/20 | 0.57 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.55 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.52 |
| ▸ | PPARG | P37231 | 7/20 | 0.52 |
| ▸ | PPARD | Q03181 | 7/20 | 0.52 |
| ▸ | PPARA | Q07869 | 7/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.52 |
| ▸ | TSHR | P16473 | 5/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | TLR2 | O60603 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | FABP4 | P15090 | 2/20 | 0.52 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.52 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1786722 | 0.97 | CES2 (0.59) | CES2CES1AKR1B1GPR84PPARG | |
| SCHEMBL6040271 | 0.97 | CES2 (0.59) | CES2CES1AKR1B1GPR84PPARG | |
| SCHEMBL10954355 | 0.97 | CES2 (0.59) | CES2CES1AKR1B1GPR84PPARG | |
| SCHEMBL8013076 | 0.95 | CES2 (0.52) | CES2CES1AKR1B1GPR84PPARG | |
| SCHEMBL543757 | 0.92 | CES1 (0.55) | CES2CES1AKR1B1GPR84PPARG | |
| SCHEMBL9127298 | 0.87 | CES2 (0.48) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL6961963 | 0.86 | CES1 (0.50) | CES2CES1AKR1B1GPR84PPARG | |
| SCHEMBL8120301 | 0.85 | CES2 (0.52) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL6969726 | 0.84 | CES1 (0.48) | CES2CES1AKR1B1GPR84PPARG | |
| SCHEMBL9126716 | 0.83 | CES2 (0.45) | CES2CES1GPR84PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3421454-B9 | PIPERIDINE DERIVATIVE | OTSUKA PHARMA CO LTD (JP) | 2023-08-09 | — | — | EP | disclosed |
| EP-3421454-B1 | PIPERIDINE DERIVATIVE | OTSUKA PHARMA CO LTD (JP) | 2023-04-05 | — | — | EP | disclosed |
| US-10851079-B2 | Piperidine derivative | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-12-01 | — | — | US | disclosed |
| US-10464926-B2 | Heterobicyclic compounds and their use for the treatment of tuberculosis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-11-05 | — | — | US | disclosed |
| EP-3186240-B1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2019-06-12 | — | — | EP | disclosed |
| US-20190040039-A1 | PIPERIDINE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-02-07 | — | — | US | disclosed |
| EP-3421454-A1 | PIPERIDINE DERIVATIVE | Otsuka Pharmaceutical Co., Ltd. (JP) | 2019-01-02 | — | — | EP | disclosed |
| US-20180312488-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-11-01 | — | — | US | disclosed |
| US-10053446-B2 | Heterobicyclic compounds and their use for the treatment of tuberculosis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-08-21 | — | — | US | disclosed |
| US-20170253576-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-09-07 | — | — | US | disclosed |
| EP-1352650-A1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | Institute of Medicinal Molecular Design, Inc. (JP) | 2003-10-15 | — | — | EP | disclosed |
| US-6627288-B1 | Optical recording medium and porphycene compound | MITSUI CHEMICALS, INC. (JP) | 2003-09-30 | — | — | US | disclosed |
| US-20030091931-A1 | Benzbisazole compound and optical recording medium containing the compound | MITSUI CHEMICALS, INC. (JP) | 2003-05-15 | — | — | US | disclosed |
| EP-1262966-A2 | Optical recording medium and novel azaporphyrin compound | Mitsui Chemicals, Inc. (JP) | 2002-12-04 | — | — | EP | disclosed |
| EP-1247655-A1 | OPTICAL RECORDING MEDIUM AND NOVEL AZAPORPHYRIN COMPOUNDS | Mitsui Chemicals, Inc. (JP) | 2002-10-09 | — | — | EP | disclosed |
| EP-1245571-A1 | BENZBISAZOLE COMPOUND AND OPTICAL RECORDING MEDIUM CONTAINING THE COMPOUND | Mitsui Chemicals, Inc. (JP) | 2002-10-02 | — | — | EP | disclosed |
| EP-1180765-A1 | Optical recording medium and porphycene compound | Mitsui Chemicals, Inc. (JP) | 2002-02-20 | — | — | EP | disclosed |
| EP-0749974-B1 | PHOSPHONIC DIESTER DERIVATIVE | OTSUKA PHARMA CO LTD (JP) | 2001-06-27 | — | — | EP | disclosed |
| US-5798344-A | TREATING DIABETES, HYPERLIPIDEMIA | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1998-08-25 | — | — | US | disclosed |
| EP-0749974-A1 | PHOSPHONIC DIESTER DERIVATIVE | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1996-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053446-B2 | Heterobicyclic compounds and their use for the treatment of tuberculosis | FNTB, SLC11A2, TBCD | CES2 2217/4885CES1 3673/4885AKR1B1 3562/4885 |
| US-20030091931-A1 | Benzbisazole compound and optical recording medium containing the compound | DAO, CACNA1I, KCNB2 | CES2 1387/4885CES1 2771/4885AKR1B1 1889/4885 |
| US-10464926-B2 | Heterobicyclic compounds and their use for the treatment of tuberculosis | FNTB, SLC11A2, TBCD | CES2 2217/4885CES1 3673/4885AKR1B1 3562/4885 |
| US-20180312488-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | FNTB, SLC11A2, TBCD | CES2 2217/4885CES1 3673/4885AKR1B1 3562/4885 |
| US-20170253576-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | FNTB, SLC11A2, TBCD | CES2 2217/4885CES1 3673/4885AKR1B1 3562/4885 |
| US-10851079-B2 | Piperidine derivative | EP300, SLC11A2, TBC1D5 | CES2 3015/4885CES1 4097/4885AKR1B1 3420/4885 |
| US-20190040039-A1 | PIPERIDINE DERIVATIVE | EP300, SLC11A2, TBC1D5 | CES2 3015/4885CES1 4097/4885AKR1B1 3420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.